Welcome : Guest

Corvus Pharmaceuticals, Inc. (USA) - Facts, Figures and Analytical Insights

Abstract

This report presents quick facts about Corvus Pharmaceuticals, Inc., which is principally a Clinical-Stage Biopharmaceutical Company. Illustrated with 37 tables, the report showcases the company's key markets and market position as against its competitors operating in the industry.

Code: PCP-66022
Price: $1850
Company Type: Public
Pages: 39
Date: March 2017
Market Data Tables: 37

 NOTE : Select the checkbox below, and click Add to Cart button to add this report to your shopping cart.
Cancer Drugs......3
Table 1: Oncology/Hematology Drugs Market by Category Worldwide (2015) - Percentage Share Breakdown by Value Sales for Blood Cell Factors, Chemopreventatives, Chemotherapeutics, Mabs, Targeted Therapies, and Others......3
Table 2: Oncology Drug Market by Region Worldwide (2015) - Percentage Share Breakdown by Value for European Union Five, Japan, US and Others......4
Cancer Market......5
Table 3: Cancer Care Expenditure by Site Worldwide (2015) - Percentage Share Breakdown for Breast, Colorectal, Lymphoma, Lung, Prostate and Others......5
Table 4: Cancer Market by Category Worldwide (2015) - Percentage Share Breakdown by Value for Heme, Lung, Prostate, and Others......6
Table 5: Oncology Market by Cancer Type Worldwide (2015) - Percentage Share Breakdown by Value for Breast Cancer, Metastatic Colorectal Cancer, Non-Small Cell Lung Cancer, and Others......7
Table 6: Clinical Oncology Market by Region Worldwide (2015) - Percentage Share Breakdown by Value Sales for US, and Others......8
Table 7: Hereditary Oncology Market by Region Worldwide (2015) - Percentage Share Breakdown by Value Sales for US, and Others......9
Table 8: Cancer Market by Type in China (2015) - Percentage Share Breakdown by Value for Breast, Colorectal, Esophagus, Liver, Lung, Stomach and Others......10
Table 9: Oncology Market by Category in China (2015) - Percentage Share Breakdown by Value for Anti- Tumor Agents, Hormone Therapy, Immuno Suppresants and Immunostimulants......11
Table 10: Oncology Market by Segment in the US (2015) - Percentage Share Breakdown by Value for Solid Tumor and Others......12
Non Hodgkin lymphoma (NHL)......13
Table 11: Non Hodgkin lymphoma (NHL) Market by Category Worldwide (2015) - Percentage Share Breakdown by Value for Rituxan, Gazyva, and Others......13
Table 12: Non Hodgkin lymphoma (NHL) Market by Category Worldwide (2015) - Percentage Share Breakdown by Volume for Burkitt Lymphoma-Burkitt Leukemia, Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, Immunodeficiency-Associated Lymphoproliferative Disorders, Lymphoplasmacytic Lymphoma, Waldenström Macroglobulinemia, Mantle Cell Lymphoma, Mediastinal (Thymic) Large B-Cell Lymphoma, Mucosa-Associated Lymphoid Tissue (MALT) Lymphoma, Small Cell Lymphocytic Lymphoma-Chronic Lymphocytic Leukemia, T-Cell and Natural Killer (NK) -Cell Lymphoma, and Others......14
Table 13: Indolent Non Hodgkin lymphoma (NHL) Market by Category Worldwide (2015) - Percentage Share Breakdown by Value for Rituxan, Gazyva, and Others......15
Table 14: No. of Non Hodgkin lymphoma (NHL) (1L) Patients by Category in European Union (2015) - Percentage Market Share Breakdown for Rituxan, Gazyva, and Others......16
Table 15: No. of Non Hodgkin lymphoma (NHL) (R/R) Patients by Category in European Union (2015) - Percentage Market Share Breakdown for Rituxan, Gazyva, and Others......17
Table 16: No. of Indolent Non Hodgkin lymphoma (NHL) (1L) Patients by Category in European Union (2015) - Percentage Share Breakdown for Rituxan, Gazyva, and Others......18
Table 17: No. of Indolent Non Hodgkin lymphoma (NHL) (R/R) Patients by Category in European Union (2015) - Percentage Share Breakdown for Rituxan, Gazyva, and Others......19
Table 18: No. of Non Hodgkin lymphoma (NHL) Patients by Category in the US (2015) - Percentage Market Share Breakdown for Rituxan, Gazyva, and Others......20
Table 19: No. of Non Hodgkin lymphoma (NHL) (R/R) Patients by Category in the US (2015) - Percentage Market Share Breakdown for Rituxan, Gazyva, and Others......21
Table 20: No. of Indolent Non Hodgkin lymphoma (NHL) (1L) Patients by Category in the US (2015) - Percentage Share Breakdown for Rituxan, Gazyva, and Others......22
Table 21: No. of Indolent Non Hodgkin lymphoma (NHL) (R/R) Patients by Category in the US (2015) - Percentage Share Breakdown for Rituxan, Gazyva, and Others......23
Monoclonal Antibodies......24
Table 22: Antiviral Market by Segment Worldwide (2015) - Percentage Share Breakdown by Value Sales for Antiviral Drugs, Monoclonal Antibodies, Vaccines and Others......24
Table 23: Therapeutic Biologics Market by Type in China (2015) - Percentage Share Breakdown by Value for Erythropoietin (EPO), Granulocyte Colony-Stimulating Factor (GCSF), Insulin, Interferon, Interleukin, Monoclonal Antibodies (MAb), Nerve GF, Somatropin, and Others......25
Table 24: Proteins Market by Segment in China (2015) - Percentage Share Breakdown by Value for Erythropoietin (EPO), Granulocyte Colony Stimulating Factor (GCSF), Insulin, Interferon, Interleukin, Monoclonal Antibody (MAb), Nerve Growth Factor (NGF), and Somatropin......26
Table 25: Monoclonal Antibodies Market by Drugs Worldwide (2015) - Percentage Share Breakdown by Value for Avastin, Crestor, Enbrel, Humira, Lantus, Remicade and Others......27
Table 26: Drugs Market by Category Worldwide (2015) - Percentage Share Breakdown by Value for Biologics, Monoclonal Antibodies and Other Classes......28
Table 27: Therapeutic Development Market by Product Worldwide (2015) - Percentage Share Breakdown by Volume for Cell Therapy, Monoclonal Antibodies, Vaccines and Others......29
Table 28: Biotechnology Drugs by Type Worldwide (2015) - Percentage Market Share Breakdown by Value for Cell Therapy, Gene Therapy, Monoclonal Antibodies (MAB), Recombinant Hormones and Proteins, Vaccines, and Others......30
Cancer Drugs......31
Table 29: Market Shares of Leading Oncology Product Manufacturers Worldwide (2015) - Percentage Breakdown by Value for Fresenius SE & Co., and Others......31
Table 30: Market Shares of Leading Oncology/Hematology Therapeutic Providers by Value Sales Worldwide (2014) - Percentage Breakdown for AbbVie, Amgen, Inc., AstraZeneca Plc, Bristol-Myers Squibb Company, Eli Lilly and Company, F. Hoffmann-La Roche AG, GlaxoSmithKline Plc, Johnson & Johnson, Merck Ltd., Novartis AG, Pfizer, Inc., Sanofi S.A., and Others......32
Table 31: Market Shares of Leading Oncology Drug Manufacturers in China (2015) - Percentage Share Breakdown by Value for Astrazeneca, Jiangsu Hengrui Medicine Co., Ltd., Roche Group and Others......33
Table 32: Anti-Cancer Drugs Market by Product Type in China (2015) - Percentage Share Breakdown by Value for Anastrozole, Capecitabine, Cetuximab, Compound kushen, Docetaxel, Epirubicin, Erlotinib, Gefitinib, Gemcitabine, Goserelin, Interferon α-2a, Interferon α-2b, Irinotecan, Kangai, Lentinan, Letrozole, Oxaliplatin, Paclitaxel, Pemetrexed, Pidotimod, RhG-CSF, RhIL-2, Rituximab, Sorafenib, Sshenqi Fuzheng, Thymopentin, Thymosin a1, Trastuzmmab, Triptorelin, TS-1, and Others......34
Table 33: Anti-Cancer Drugs Market by Type in China (2015) - Percentage Share Breakdown by Value for Alkylating Agents, Antibiotics, Antimetabolites, Hormonal Agents, Immunostimulant, Plant Alkaloids, and Others......35
Relapsed/Refractory (RR) Indolent Non-Hodgkin's Lymphoma (iNHL)......36
Table 34: Market Shares of Leading Drugs for Treatment of Relapsed/Refractory (RR) Indolent Non-Hodgkin's Lymphoma (iNHL) in the US (2015) - Percentage Share Breakdown by Value for Ibrutinib, Idelalisib and Other......36
Table 35: Market Shares of Leading Drugs for Treatment of Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma (R/R- aNHL) in the US (2015) - Percentage Share Breakdown by Value for Ibrutinib and Others......37
Relapsed/Refractory (RR) Aggressive Non-Hodgkin Lymphoma (aNHL)......38
Table 36: Market Shares of Leading Drugs for Treatment of Relapsed/Refractory (RR) Aggressive Non-Hodgkin Lymphoma (aNHL) in the US (2015) - Percentage Breakdown by Value for ABT-199, Ibrutinib, Idelalisib, and Others......38
Monoclonal Antibodies......39
Table 37: Market Shares of Leading Monoclonal Antibody Production Companies in the US (2015) - Percentage Share Breakdown by Value for Abbvie Inc., AMGen, Johnson & Johnson, F. Hoffmann-La Roche AG and Others......39